COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Botox as a Treatment for Chronic Male Pelvic Pain Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00194623
Recruitment Status : Terminated (Reorganization of personnel forced termination.)
First Posted : September 19, 2005
Last Update Posted : October 19, 2007
Paul G. Allen Family Foundation
Information provided by:
University of Washington

Brief Summary:

Chronic pelvic pain syndrome (CPPS) is thought to affect approximately 8% of men aged 18 and older. Patients with this condition experience pain in the perineum, the genitalia, and the rectum. As well, there is associated voiding, sexual, and ejaculatory dysfunction. The impact of patient well-being is thought to be equivalent to patients with congestive heart failure. The etiology of this condition is unknown, thus making treatment very difficult. Researchers have pursued an infectious cause for the disease; however, studies have failed to substantiate this theory. Despite this, the main treatment offered to patients is long-term antibiotic therapy. Results from this treatment modality have been unsatisfactory.

Other groups have postulated that the symptoms of CPPS may be secondary to neuromuscular factors. Some studies have demonstrated increases in pelvic muscular tone. Maneuvers such as prostate massage and levator massage have shown some benefit in relieving symptoms. Treatment with alpha-blockers to relax prostate smooth muscle has brought about improvement in a portion of patients. Use of generalized muscle relaxants has produced mediocre results.

However, many of these neuromuscular treatments are generalized and do not target the perineal musculature directly. It is theorized that spasm of the perineal muscles triggered by an unknown noxious stimuli (e.g. infection) cause the pain and symptoms of CPPS. At our center, we have performed pilot studies using botulinum toxin A. Four patients were treated with Botox". 100 U were injected in three locations in the midline of the bulbocavernosus muscle. The bulbocavernosus muscle is easily accessible and shares innervation with the pelvic musculature. Patient's response to medication was measured by the NIH Prostatitis pain scale and as well as the University of Washington prostatitis pain scale. All patients reported resolution of symptoms. Remission lasted for duration of 10-12 weeks. No patients reported adverse events.


Botulinum toxin A is effective in the treatment of chronic pelvic pain syndrome in men.

Condition or disease Intervention/treatment Phase
Chronic Male Pelvic Pain Syndrome Drug: Botulinum Toxin A (Botox) Phase 4

Detailed Description:

Visit 1 Patient will review and sign the study consent form. Subject will be asked to complete questionnaires. Then, patient will then be asked to give a semen sample.

Visit 2 (1 week after Visit I) Prior to this visit, the patient will be randomized to either active medication or placebo. First, the patient will then undergo a physical exam including a genital and rectal exam. Then, the patient will be brought in to the room and placed in lithotomy position. The perineum will be prepped with iodine solution. EMG electrodes and a ground will be placed in the perineum. Three landmarks (1. middle of bulbospongiosus muscle; 2. perineal body; 3. an area equidistant from 1 and 2) will be marked using a skin marker. The EMG needle will be placed into each landmark and the patient will be asked to squeeze his perineal muscles. Once in the proper location, 1.3 cc of medication (active drug or placebo) will be distributed into these landmarks. The remaining 2.6 ccs will be injected into 2 other painful pelvic muscle sites as determined physical exam. The area will then be gently massaged.

  1. Month Post Injection Mailing:

    The patient will be mailed a packet containing follow-up questionnaires.

  2. Month Post Injection Mailing: Same as 1 Month Post Injection Visit.
  3. Month Post Visit (Visit 3) First, the subject will be asked to fill out follow-up questionnaires. Next, a physical exam and prostate massage will be performed and expressed prostatic secretions collected. Finally, the subject will be asked to provide a semen sample.

Optional open label trial for those patients randomized to placebo section:

Open label injection visit (Visit 4) Injection of open label Botox as in Visit 2.

  1. Month Post Open Label Botox Injection Mailing:

    The patient will be mailed a packet containing follow-up questionnaires.

  2. Month Post Open Label Botox Injection Mailing:

    Same as 1 Month Post Injection mailing.

  3. Month Post Open Label Injection Visit:

Same as Visit 3.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial
Study Start Date : August 2003
Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox Pelvic Pain

Primary Outcome Measures :
  1. NIH-CPSI -pain scores at 3 months post-treatment follow-up [ Time Frame: 3 months post treatment ]

Secondary Outcome Measures :
  1. AUA score at 3 months post-treatment follow-up [ Time Frame: 3 months post-treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men aged 18 and older
  • History of chronic pelvic pain syndrome (NIH type IIIA and IIIB) for at least 3 months
  • No antibiotics or new treatment for prostatitis for at least 30 days
  • Written informed consent and written authorization for use or release of health and research study information have been obtained.
  • Subject has severity/stage of disease: pain areas must include perineum.
  • Laboratory findings required : negative urine cultures.
  • Ability to follow study instructions and likely to complete all required visits.

Exclusion Criteria:

  • Documented urinary tract infection
  • Bacteria isolated to the prostate from segmental urine cultures
  • Pain from another source in the genitourinary tract (e.g. renal colic)
  • Genitourinary (GU) malignancy
  • History of radiation to the GU tract
  • Previous or current botulinum therapy
  • Known allergy or sensitivity to any study medication (Botox, lidocaine)
  • Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, spinal cord injury or any other significant disease which might interfere with neuromuscular transmission
  • Concurrent use of aminoglycoside antibiotics or agents that interfere with neuromuscular transmission
  • Profound atrophy or excessive weakness of the muscles to be injected
  • Infection at the injection site or systemic infection
  • Concurrent participation in another investigational drug study
  • Is overtly psychotic or suicidal.
  • Has post-surgical pain
  • Has back or rectal pain only.
  • Was treated for prostate, bladder, renal or other genitourinary malignancy
  • Had in the past or is currently undergoing radiation therapy
  • Has a history of genitourinary tuberculosis
  • Is currently taking antibiotics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00194623

Sponsors and Collaborators
University of Washington
Paul G. Allen Family Foundation
Layout table for investigator information
Principal Investigator: Richard E Berger, MD Professor of Urology
Layout table for additonal information Identifier: NCT00194623    
Other Study ID Numbers: 02-5458-A 04
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: October 19, 2007
Last Verified: October 2007
Keywords provided by University of Washington:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pelvic Pain
Somatoform Disorders
Pathologic Processes
Mental Disorders
Neurologic Manifestations
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents